With the White House aiming for a Sept. 20 start date for COVID-19 booster shots for adults in the U.S., the countdown has begun for the U.S. Food and Drug Administration (FDA) to review booster data from vaccine companies. Moderna (MRNA), meanwhile, is focused on halving its booster shot, from the current 100 microgram dose. The company submitted to the FDA an initial round of data to support the half dose this week. According to Moderna officials, the lower dosage has production benefits… Source link
Read More »Moderna CEO sees likely need for COVID booster for high-risk groups later this year
Moderna (MRNA) has its sights set on 2022 and beyond, even as it continues to produce doses for its COVID-19 vaccine this year. CEO Stéphane Bancel told Yahoo Finance Wednesday that governments are now focused on booster shots for next year, even though it’s unclear what type of booster shot will be needed — or when it will be needed — as worries surface over emerging variants. The pandemic still continues to claim casualties around the world, challenging efforts by the U.S., Britain… Source link
Read More »